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Long-chain ω-3 polyunsaturated fatty acids (PUFAs) are known to induce cardiometabolic benefits, but the metabolic pathways of
their biosynthesis ensuring sufficient bioavailability require further investigation. Here, we show that a pharmacological decrease in
overall fatty acid utilization promotes an increase in the levels of PUFAs and attenuates cardiometabolic disturbances in a Zucker
rat metabolic syndrome model. Metabolome analysis showed that inhibition of fatty acid utilization by methyl-GBB increased the
concentration of PUFAs but not the total fatty acid levels in plasma. Insulin sensitivity was improved, and the plasma insulin
concentration was decreased. Overall, pharmacological modulation of fatty acid handling preserved cardiac glucose and
pyruvate oxidation, protected mitochondrial functionality by decreasing long-chain acylcarnitine levels, and decreased
myocardial infarct size twofold. Our work shows that partial pharmacological inhibition of fatty acid oxidation is a novel
approach to selectively increase the levels of PUFAs and modulate lipid handling to prevent cardiometabolic disturbances.
1. Introduction
The combination of interrelated metabolic risk factors such
as obesity, dysglycaemia, dyslipidaemia, and insulin resis-
tance creates the basis of metabolic syndrome [1, 2] and pro-
motes the development of cardiovascular diseases and type 2
diabetes mellitus. Metabolic syndrome, when compared to
obesity, is related to a higher incidence of major coronary
events, including fatal and nonfatal myocardial infarctions
[3] and is also associated with increased 20-year mortality
in patients [4]. While obesity can be effectively treated by life-
style and dietary adjustments [5] and/or bariatric surgery [6],
a much broader strategy including drug therapy is required
to tackle metabolic syndrome [2]. To ensure better transla-
tion of novel cardiometabolic therapies to the clinical setting,
multiple cardiovascular risk factors and comorbidities should
be taken into account when evaluating compounds in a pre-
clinical setting [7–9].
Multiple studies have found an association between the
consumption of fish containing omega-3 polyunsaturated
fatty acids (PUFAs) and improved cardiovascular outcomes
[10]. In contrast, a recent meta-analysis of 23 randomized,
double-blind, placebo-controlled trials in cardiovascular
patients did not show a protective effect of an additional
intake of eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) on total mortality and cardiovascular mortality,
particularly in the presence of statins [11]. Of interest for
the treatment of complications of metabolic syndrome could
be finding in a rat model that treatment with ω-3 PUFAs
decreases the severity of postresuscitation myocardial dys-
function, lipid peroxidation, and systemic inflammation in
the early phase of recovery following cardiac arrest [12].
Likewise, transgenic fat-1 mice with constantly elevated
levels of endogenous ω-3 PUFAs have preserved cardiac con-
tractile function and less inflammation and oxidative stress
when challenged with LPS than wild type animals [13]. In
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insulin-resistant states, an increased reliance of cardiomyo-
cytes on the oxidation of free fatty acids is present and asso-
ciated with both a lower yield of ATP per oxygen molecule
and likely decreased energetic efficiency [14]. It should be
noted that complete oxidation of PUFAs is more than 2 times
faster than the oxidation of saturated fatty acids [15]. Thus,
one can assume that dietary PUFAs are less likely to accumu-
late to reach the levels/ratios required to induce beneficial
effects. In turn, as PUFAs are the preferred substrate [16]
for mitochondrial fatty acid metabolism, inhibition of over-
all fatty acid oxidation could lead to a comparably higher
increase in the levels of PUFAs but not saturated fatty
acids. Interestingly, plasma lipid parameters are normal-
ized, and the levels of several short- to medium-chain acyl-
carnitines are significantly decreased by up to 30% after
treatment with PUFAs [17]. Altogether, we hypothesized
that long-term pharmacological inhibition of carnitine pal-
mitoyltransferase I- (CPT I-) dependent mitochondrial
fatty acid metabolism increases the levels of PUFAs and
could induce anti-infarction activity in a Zucker rat meta-
bolic syndrome model.
The aim of the present study was to test whether treat-
ment with the carnitine/acylcarnitine-lowering compound
methyl-GBB (4-[ethyl(dimethyl)ammonio]butanoate) can
decrease overall fatty acid oxidation, thus increasing PUFA
availability; and could these alterations in lipid metabolism
reduce ischaemia-reperfusion (I/R)-induced cardiac damage
in Zucker rats with metabolic syndrome? Zucker rats were
used as a representative preclinical model of continuous
nutritional overload, physical inactivity, and abdominal obe-
sity, which over time lead to the development of metabolic
syndrome [18, 19].
2. Materials and Methods
2.1. Animals and Treatment. Zucker fa/fa male rats (n = 36)
and age-matched (5-7-week-old, ~140 g at the time of pur-
chase) Zucker lean male rats (n = 18) were obtained from
Charles River, and 18 C57BL/6JOlaHsd inbred mice (4-6
weeks old, ~18 g at the time of purchase) were obtained from
Envigo. Animals were housed for one week prior to treat-
ment under standard conditions (21-23°C, 12-h light/dark
cycle, relative humidity 45-65%) with unlimited access to
food R70 diet from Lantmännen and water. The experimen-
tal procedures were performed in accordance with the guide-
lines of the European Community and local laws and policies
(Directive 2010/63/EU), and all of the procedures were
approved by the Food and Veterinary Service, Riga, Latvia.
All experiments were performed in a blinded manner. Stud-
ies involving animals are reported in accordance with the
ARRIVE guidelines [20, 21].
By limiting the availability of long-chain acylcarnitines
(LCAC), methyl-GBB (5–20mg/kg) significantly decreases
infarct size (IS) ex vivo by approximately 50% in normogly-
caemic animals [22, 23]. In the present study, a dose of
10mg/kg was chosen based on previous data regarding
methyl-GBB cardiac tissue levels, the effects on carnitine/
acylcarnitine levels, cardioprotection in normoglycaemic
animals, and data from models with impaired energy metab-
olism. Although ex vivo methyl-GBB, even at a dose of
5mg/kg, induces a maximal decrease in IS [23], in pre-
vious studies using high-fat diet-fed ApoE-/- knockout
mice, methyl-GBB at a dose of 10mg/kg was required
to significantly decrease atherosclerotic lesions and dysli-
pidaemia [24], two major factors contributing to meta-
bolic syndrome.
Data from previous experiments where I/R damage was
determined in methyl-GBB-treated animals were subjected
to statistical power analysis, and calculations indicated that
n = 10 for the infarction study would produce significant
results with power > 0:9. Animals were randomly separated
into two experimental groups and given daily oral doses of
water (Zucker fa/fa control group, n = 10) or 10mg/kg
methyl-GBB (Zucker fa/fa methyl-GBB group, n = 10) for
12 weeks (18 weeks old at the time of infarction study).
Zucker lean rats (n = 10) were used as a nonhyperlipidaemic
control. To assess mitochondrial levels of acylcarnitines,
changes in glucose utilization, molecular pathway upregula-
tion, and mitochondrial functionality, additional experi-
ments were performed in animals treated as described
above. Animals were separated randomly into two experi-
mental groups and given daily oral doses of water (Zucker
fa/fa control group, n = 8) or 10mg/kg methyl-GBB (Zucker
fa/fa methyl-GBB group, n = 8). Zucker lean rats (n = 8)
were used as a nonhyperlipidaemic control. Additional
experiments to determine plasma EPA, DHA, and free fatty
acid (FFA) concentrations were performed in normoglycae-
mic C57BL/6 mice. Mice were separated randomly into two
experimental groups and given daily oral doses of water
(mouse control group, n = 9) or 5mg/kg methyl-GBB
(mouse methyl-GBB group, n = 9) for 4 weeks. For all
experiments, nonfasting or postovernight-fasting blood
samples were collected from tail veins; samples were centri-
fuged, and the plasma was stored at -80°C for future
analysis.
2.2. Isolated Rat Heart Infarction Study. The infarction was
performed according to the Langendorff technique as
described previously [25, 26], with some modifications.
Animals were anaesthetized with sodium pentobarbital
(70mg/kg), and after the loss of nociceptive reflexes, hearts
were immediately excised, thus, sacrificing animals. Hearts
were retrogradely perfused with Krebs-Henseleit (KH) buffer
solution supplemented with 10mM glucose (Fresenius Kabi),
0.3mM sodium palmitate (TCI Europe) bound to 0.5%
bovine serum albumin (BSA) (Europa Bioproducts Ltd.),
2mM lactate (Fischer Scientific), 0.2mM pyruvate (Acros
Organics), and 3ng/ml insulin aspart (Novo Nordisk) at a
constant perfusion pressure of 70mmHg. After an adapta-
tion period of 20min, the left anterior descending coronary
artery (LAD) was subsequently occluded for 30min followed
by 120min of reperfusion. IS was determined as described
previously [26]. Heart functional parameters, coronary flow,
left ventricle developed pressure (LVDP), heart rate, and car-
diac workload were registered using the PowerLab system
from ADInstruments. Briefly, at the end of reperfusion, the
LAD was reoccluded, and the heart was perfused with 0.1%
methylene blue dissolved in KH buffer solution to delineate
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risk and no-risk areas. Afterwards, the ventricles of the heart
were transversely cut into 2mm thick slices and photo-
graphed. Computerized planimetric analysis of the stained
left-ventricle slice photographs was performed using Image-
Pro Plus v6.3 software to determine the area at risk (AR)
and the area of necrosis (AN), and each area was expressed
as a percentage of the slice area. The obtained values were
then used to calculate the IS as a percentage of the risk area,
based on the formula IS = AN/AR × 100%.
2.3. Determination of Glucose Oxidation in Isolated Hearts.
The rate of radiolabelled glucose oxidation was measured in
additional sets of rat hearts according to a method previously
described [22, 23] with the following modifications. Glucose
oxidation measurement was performed according to the
Langendorff perfusion technique. The hearts were perfused
retrogradely (constant perfusion pressure, 70mmHg) with
KH buffer solution supplemented with 10mM glucose,
0.3mM sodium palmitate bound to 0.5% bovine serum albu-
min (BSA), 2mM lactate, 0.2mM pyruvate, and 3 ng/ml
insulin. After a 10min adaptation time, the perfusate was
switched to the oxygenated radiolabelled KH buffer solution,
and perfusion was continued for 10min at a constant pressure.
The glucose oxidation rate was determined by measuring the
14CO2 released from the metabolism of [U-
14C]glucose (spe-
cific activity, 300mCi/mmol).
2.4. Mitochondrial Energy Metabolism. The mitochondrial
energy metabolism was determined in the permeabilized car-
diac fibres prepared as described previously [25, 27] with
some modifications. The bundles of fibres were perme-
abilized using 50μg/ml saponin (Acros Organics) and
0.5mg/ml collagenase (Sigma-Aldrich) at 4°C in 1ml of
buffer A (20mM imidazole, 20mM taurine (all Acros
Organics), 0.5mM dithiothreitol (Tocris Bioscience),
7.1mM MgCl2 (Penta Chemicals), 50mM MES, 5mM
ATP, 15mM phosphocreatine, 2.6mM CaK2EGTA, and
7.4mM K2EGTA (all Sigma-Aldrich), pH7.0 at 0
°C). After
a 15min incubation, the fibres were washed for 15min in
2ml of buffer B (20mM imidazole, 0.5mM dithiothreitol,
20mM taurine, 1.6mM MgCl2, 100mM MES, 3mM
KH2PO4 (Enola Ltd), 2.9mM CaK2EGTA, 7mM K2EGTA,
pH7.1 at 37°C).
High-resolution fluorespirometry was performed using
Oxygraph-2 k (O2k; OROBOROS INSTRUMENTS). All
experiments were performed at 37°C in MiR05 medium
(110mM sucrose (Enola Ltd.), 60mMK-lactobionate
(Sigma-Aldrich), 0.5mM EGTA (Sigma-Aldrich), 3mM
MgCl2, 20mM taurine, 10mM KH2PO4, 20mM HEPES
(Acros Organics), pH7.1 at 30°C, and 0.1% essential fatty
acid free BSA). The medium was reoxygenated when the oxy-
gen concentration dropped to 80μM. Palmitoyl-CoA
(10μM) (Larodan AB), carnitine (500μM for Zucker lean
rats and Zucker fa/fa control rats and 20μM for methyl-
GBB-treated rats), and malate (0.5mM) (Acros Organics)
were used to measure CPT I-linked fatty acid oxidation
(FAO) dependent on the LEAK state. ADP (Sigma-Aldrich)
was added to a concentration of 5mM to determine oxidative
phosphorylation-dependent respiration (OXPHOS state).
The FA oxidation-dependent OXPHOS coupling efficiency
was calculated as follows:
1 – Resp:rate LEAK stateResp:rate OXPHOS state : ð1Þ
Then, pyruvate (5mM) was added to determine the pyru-
vate and FA metabolism interaction. The pyruvate-
dependent flux control factor was calculated as
1 − Resp:rate before the addition of pyruvate PCoAOXPHOSð ÞResp:rate after the addition of pyruvate PCoA + pyruvate OXPHOSð Þ :
ð2Þ
2.5. Determination of Reactive Oxygen Species (ROS)
Production. H2O2 flux (ROS flux) in cardiac fibres was mea-
sured simultaneously with respirometry using an O2k-
Fluorometer and the H2O2-sensitive probe Ampliflu™ Red
(AmR) (Sigma-Aldrich) as described previously [27, 28] with
some modifications. First, 10μM AmR, 1U/ml horseradish
peroxidase (HRP), and 5U/ml superoxide dismutase (SOD)
(all Sigma-Aldrich) were added to the chamber, and H2O2
detection was performed based on the conversion of AmR
to fluorescent resorufin. Calibrations were performed by
adding 0.1μM H2O2 stepwise. The H2O2 flux was corrected
to take into account the background (AmR slope before sam-
ple addition). The respiration protocol was similar to that
described above, with the exception that after the assessment
of FAO and pyruvate-linked respiration, succinate (10mM,
complex II (CII) substrate) (Sigma-Aldrich) was then added
to reconstitute convergent FAO-CI-II-linked respiration.
Then, an inhibitor of adenine nucleotide translocator, car-
boxyatractyloside (Catr) (Sigma-Aldrich), was added to
determine the LEAKCatr respiration. Titration with an
uncoupler, carbonyl cyanide m-chlorophenyl hydrazine
(0.5μM steps to maximum oxygen consumption) (Sigma-
Aldrich), was performed to determine the H2O2 production
rate at the electron transfer system capacity state.
2.6. mRNA Isolation and qPCR Analysis. Total RNA from the
heart tissues was isolated using TRI reagent (Sigma-Aldrich),
and first-strand cDNA synthesis was carried out using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems™) following the manufacturer’s instructions. qPCR
analysis of gene expression was performed by mixing SYBR®
Green Master Mix (Applied Biosystems™) with synthesized
cDNA and forward and reverse primers specific for carnitine
palmitoyltransferase IA (CPT IA) and IB (CPT IB), long-
chain fatty acid CoA synthetase (ACSL), pyruvate dehydro-
genase lipoamide kinase isozyme 4 (PDK4), acyl-CoA
oxidase 1 (ACOX), and valosin-containing protein (VCP)
and running the reactions on a Bio-Molecular Systems MIC
qPCR Cycler according to manufacturer’s protocol using fol-
lowing conditions: 95°C for 10 minutes, (95°C for 15 seconds,
60°C for 60 seconds) (60 cycles), 95°C for 60 seconds,
followed by melt curve analysis 72-95°C, 0.3°C/sec to ensure
amplicon specificity. The relative expression levels for each
gene were calculated with the ΔΔCt method and normalized
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to the expression of VCP. The primer sequences used for the
qPCR analysis are available upon request.
2.7. Western Blot Analysis of Tissue Lysates.Heart muscle tis-
sues were homogenized with an Omni Bead Ruptor 24
homogenizer (Omni International) at a ratio of 1 : 10 (w/v)
at 4°C in a buffer containing 100mM Tris-HCl (Acros
Organics), pH7.4, 10mM EDTA (Sigma-Aldrich), 5mM
MgCl2, 1mM glycerol 3-phosphate, 1mM NaF (all from
Fluka), 500μM Na3VO4 (Sigma-Aldrich), 1mM DTT
(Tocris Bioscience), phosphatase inhibitor cocktail I 1 : 100
(Alfa Aesar), protease inhibitors (10μM leupeptin, 1μM
pepstatin (both from Tocris Bioscience), 1μM aprotinin,
and 100μM AEBSF (both from Sigma-Aldrich)). Total pro-
tein was detected using the Lowry method. SDS-PAGE and
Western blotting were performed as described previously
with some modifications [29]. Briefly, 20μg of total protein
was loaded into Bolt™ 4-12% Bis-Tris Plus Gels (Thermo Sci-
entific). After transfer, the polyvinylidene fluoride mem-
branes (Thermo Scientific) were blocked with 5% BSA
(Sigma-Aldrich) in Tris-buffered saline (TBS) for 1 h at room
temperature and then incubated overnight at 4°C with pri-
mary antibodies. After washing with TBS, the blots were
incubated for 1 h at room temperature with secondary
peroxidase-coupled goat anti-rabbit IgG (lot: 26, #7074 Cell
Signaling Technology) and then washed again with TBS.
The blots were developed using chemiluminescence reagents
(Millipore) and an Azure c400 Imaging System. TheWestern
blot images were analysed using AzureSpot2.0 software. The
phosphorylation levels of Akt at Ser473 on the membranes
were detected with a phospho-Akt Ser473 (lot: 23, #4060 Cell
Signaling Technology) antibody, and the obtained data were
normalized to the total Akt level (lot: 20, #4691 Cell Signaling
Technology).
2.8. Determination of Biochemical Measures. The plasma
insulin concentrations were determined using a Sensitive
Rat Insulin RIA Kit. Blood glucose was measured using a
MediSense Optium glucometer from Abbott Diabetes Care.
The concentration of FFAs was determined using a kit from
Wako in plasma, and lactate was determined using a kit from
Roche Diagnostics. Triglycerides, total cholesterol, aspartate
aminotransferase (ASAT), and alanine aminotransferase
(ALAT) in plasma were determined using kits from Instru-
mentation Laboratory. HOMA-IR was calculated according
to the formula
fasting insulin μU/Lð Þ x fasting glucose
22:5 : ð3Þ
2.9. Measurement of Carnitine, Methyl-GBB, Acylcarnitines,
and Poly-Unsaturated Fatty Acids by UPLC/MS/MS and
Metabolomics. The determination of carnitine and methyl-
GBB in heart tissues and plasma samples was performed by
ultraperformance liquid chromatography-tandem mass
spectrometry (UPLC/MS/MS) using the positive ion electro-
spray mode [23]. Mitochondria samples were prepared as
previously described [30], and acylcarnitines were analysed
by the UPLC MS/MS method [29]. PUFAs were measured
as follows: 200μl of acetonitrile–methanol mixture (3 : 1, v/
v) were added to 40μl of plasma samples or calibration sam-
ple solution. The samples were thoroughly mixed and centri-
fuged for 10min at 10000 rpm, and the supernatants were
subjected to UPLC/MS/MS analysis. The analysis was per-
formed on Acquity UPLC system coupled with Xevo TQ-S
microtriple-quadrupole mass spectrometer (Waters Corp.).
The separation of analytes was carried out on an Acquity
UPLC BEH C18 column (2:1 × 50mm, 1.7μm, Waters
Corp.) operated at 30°C under a gradient elution from 40 to
98% acetonitrile in 0.1% FA. Flow rate was 0.4ml/min, and
injection volume was 1μl. The mass spectrometer was oper-
ated using an electrospray ionization source in negative ion
mode. The multiple reaction monitoring (MRM) mode was
employed for quantitative determination of target com-
pounds. The main ionization settings were optimized as fol-
lows: capillary voltage of 2.0 kV; source and desolvation
temperatures of 140 and 600°C, respectively; desolvation
gas (nitrogen) flow of 800 L/h. Cone voltage (V) and collision
energy (eV) values were specified for each compound: 20 and
15 for EPA; 20 and 12 for DHA, respectively. Quantitative
analysis was performed under MRM mode by calculating
the peak areas. Precursor to product ion transitions m/z
301.29→ 203.31 and 301.29→ 257.45 for EPA and m/z
327.30→ 229.35 and 327.30→ 283.35 for DHA were moni-
tored. Data acquisition and processing were performed using
the MassLynx V4.1 and QuanLynx V4.1 software (Waters
Corp.). The samples were kept at 10°C in the autosampler.
The calibrators were run in triplicate and the samples in
duplicate. Concentrations of EPA, DHA, and FFAs (C12-
C20) were measured in mice plasma samples by Biocrates
Life Sciences AG (Innsbruck, Austria) as a part of their
metabolomics analysis service by using Biocrates MxP
Quant 500 Kit.
2.10. Statistical Analysis. The data are presented as the
mean ± S:E:M: (standard error of the mean). Based on a
normality test (D’Agostino & Pearson omnibus normality
test (Shapiro-Wilk normality test if N = 7 or lower)) of the
data, statistically significant differences in the mean values
were evaluated using one-way ANOVA or the Kruskal-
Wallis test. If ANOVA indicated P < 0:05, Tukey’s test was
performed, and the differences were considered significant
when P < 0:05. If the Kruskal-Wallis test indicated P < 0:05
, Dunn’s multiple comparison test was performed, and the
differences were considered significant when P < 0:05. The
data were analysed using GraphPad Prism statistical soft-
ware (GraphPad Inc., USA). For IS determination, 1 heart
could not be analysed in the methyl-GBB-treated rat group,
and 3 hearts could not be analysed in the Zucker lean rat
group due to isolated heart perfusion system tubing failure.
To determine functional heart parameters, LCAC levels,
and metabolic patterns, an additional experiment was per-
formed; 1 sample could not be analysed in the Zucker fa/fa
rat control group, as the animal died suddenly of natural
causes, and the data represent the mean values of N = 7 for
this group. The data and statistical analyses comply with
the recommendations for experimental design and analysis
in pharmacology [31].
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2.11. Materials.Methyl-GBB (a phosphate salt) was obtained
from JSC Grindeks (Riga, Latvia). An insulin RIA kit was
purchased from Millipore (USA) and [U-14C]glucose was
purchased from Biotrend Chemikalien GmbH (Germany).
3. Results
3.1. Plasma Concentrations of EPA, DHA, and Lipid Species.
First, data on EPA and DHA plasma concentrations were
obtained from normoglycaemic mice treated with methyl-
GBB for 4 weeks at a dose of 5mg/kg. EPA and DHA plasma
concentrations in methyl-GBB-treated mice were signifi-
cantly increased 3.4- and 1.9-fold in plasma from fasted mice,
respectively, and 2.5- and 2.3-fold in plasma from fed mice,
respectively (Supplementary Figure 1). Moreover, the
concentration of FFAs (sum of C12-C20) was 1.3-fold
increased only in fasted mouse plasma after treatment with
methyl-GBB (Supplementary Figure 2). Next, in Zucker
rats, plasma concentrations of EPA and DHA were
measured after 12 weeks of treatment with methyl-GBB at a
dose of 10mg/kg. No significant difference was observed
between EPA levels in the Zucker lean and Zucker fa/fa rat
control groups, although there was a tendency for higher
EPA concentrations in the Zucker fa/fa control group.
Methyl-GBB treatment resulted in a significant 6.3- and
2.3-fold increase in the plasma EPA concentration
compared to the Zucker lean rat and Zucker fa/fa rat
control groups (Figure 1(a)). DHA levels were similar in
the Zucker lean and Zucker fa/fa control groups. Treatment
with methyl-GBB increased the DHA concentration 2.1-
fold, but the effect was not statistically significant
(Figure 1(b)). The carnitine levels in the Zucker lean and
Zucker fa/fa rat hearts were similar, while in the methyl-
GBB-treated rat hearts, the carnitine level was significantly
decreased by 95% (Figure 1(c)). The LCAC content was
determined in isolated cardiac mitochondria. Interestingly,
the LCAC content in isolated cardiac mitochondria after
I/R was 52% lower in the Zucker fa/fa control rat group
than in the Zucker lean rat group; however, this effect was
not statistically significant. Treatment with methyl-GBB
significantly decreased the heart mitochondrial content of
LCAC 25-fold compared to the Zucker fa/fa control group
(Figure 1(d)).
In the fed state, the concentration of FFAs in plasma was
significantly higher in the Zucker fa/fa control and methyl-
GBB-treated Zucker fa/fa rats than in the Zucker lean rats
(Figure 1(e)). Similarly, the concentrations of triglycerides
and total cholesterol in plasma were significantly higher in
the fed Zucker fa/fa control and methyl-GBB-treated Zucker
fa/fa rats than in the Zucker lean rats (Table 1). Methyl-GBB
treatment had no significant effect on the ASAT and ALAT
levels when compared to the Zucker fa/fa rat control group.
While methyl-GBB treatment significantly increased the
PUFA content by up to 2.3-fold (Figures 1(a) and 1(b)), only
a nonsignificant tendency to increase the total FFA concen-
tration by 30% in the methyl-GBB-treated group was
observed when compared to the Zucker fa/fa control group
(Figure 1(e)). Zucker fa/fa rats gained significantly more
weight than Zucker lean rats, and methyl-GBB had no effect
on weight gain or on the organ-to-body weight ratio. Overall,
while treatment with methyl-GBB significantly increased
plasma concentrations of PUFAs, it had no effect on other
lipid species.
3.2. Isolated Rat Heart Infarction and Haemodynamic
Parameters and Mitochondrial Function after Ischaemic
Damage. A heart infarction study was performed after 12
weeks of treatment with methyl-GBB at a dose of 10mg/kg.
Treatment with methyl-GBB significantly decreased the
myocardial IS by 51% (Figure 2(b)) compared to the Zucker
fa/fa rat control group. The IS in the methyl-GBB-treated
group was also significantly lower (46%) than that of the
Zucker lean rat group. There was no statistically significant
difference between the area at risk (AR) values in the Zucker
fa/fa rat control group and in the methyl-GBB-treated
Zucker fa/fa groups. The AR value in the Zucker fa/fa control
group was significantly larger by 36% than that in the Zucker
lean rat group (Figure 2(a)). As in previous studies in healthy
animals, methyl-GBB treatment had no significant effect on
normoxic heart functional parameters in Zucker fa/fa rats
when compared to the Zucker fa/fa control group
(Figures 2(c)–2(g)). Coronary flow during LAD occlusion
was decreased by 40% in the Zucker lean rat group and by
43% and 45% in the Zucker fa/fa control and methyl-GBB-
treated groups, respectively (Figure 2(c)). During reperfu-
sion, recovery of coronary flow was significantly better in
the methyl-GBB-treated group than in the Zucker fa/fa con-
trol group. During reperfusion, LVDP (Figure 2(d)) was sig-
nificantly higher in methyl-GBB-treated rat hearts than in
Zucker lean and Zucker fa/fa rat hearts, and a tendency to
preserve cardiac workload (Figure 2(g)) was observed in
methyl-GBB-treated Zucker rat hearts. Methyl-GBB treat-
ment had no effect on heart rate when compared to the
Zucker fa/fa control group (Figure 2(e)). Heart contractility
at the end of reperfusion was significantly higher by 67 and
64% in the methyl-GBB-treated group than in the Zucker
lean rat and Zucker fa/fa control groups, respectively
(Figure 2(f)).
To evaluate the effects of methyl-GBB treatment onmito-
chondrial functionality after ischaemic damage, perme-
abilized cardiac fibres were compared from both nonrisk
(NR) and AR regions of the heart. In the presence of carnitine
concentrations that mimic the tissue carnitine content,
methyl-GBB decreased the CPT I-dependent OXPHOS cou-
pling efficiency with palmitoyl-coenzyme A (PCoA) in nor-
moxic cardiac fibres and after reperfusion, indicating an
overall decrease in FAO (Figure 2(h)). Interestingly, in the
Zucker fa/fa control group after reperfusion, no increase in
the PCoA-dependent OXPHOS coupling efficiency was
observed when risk and normoxic nonrisk areas were com-
pared. In contrast, fatty acid metabolism during reperfusion
was increased by 34% in cardiac fibres from AR regions from
methyl-GBB-treated rat hearts compared to normoxic NR
areas from these hearts. In addition, methyl-GBB significantly
increased pyruvate metabolism in both normoxic and reper-
fused tissues (Figure 2(h)). I/R tended to increase mitochon-
drial reactive oxygen species (ROS) production in the
OXPHOS state and significantly increased ROS production
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in the LEAKCatr state compared to normoxic conditions.
Methyl-GBB treatment prevented an increase in ROS produc-
tion, particularly in the LEAKCatr state (Figure 2(i)). Together,
treatment withmethyl-GBB optimizes energymetabolism and
preserves mitochondrial functionality.
3.3. Insulin Sensitivity and Energy Metabolism Regulation.
The glucose concentration was similar in fed Zucker lean
and Zucker fa/fa rat blood (Figure 3(a)). In the fasted state,
the blood glucose concentration in Zucker fa/fa rats was sig-
nificantly higher (26%) than that of fasted Zucker lean rats
(Figure 3(a)). In addition, insulin concentrations were signif-
icantly 22- and 13-fold higher in Zucker fa/fa rat plasma than
in Zucker lean rats in the fasted and fed states, respectively.
Treatment with methyl-GBB significantly decreased plasma
insulin concentrations by 42% and 40% in the fasted and
fed states, respectively (Figure 3(b)). The homeostasis model
assessment of insulin resistance (HOMA-IR) value for
healthy Zucker lean rats was 1.38, while it was 30.5-fold
higher in the Zucker fa/fa control group. Treatment with
methyl-GBB significantly decreased the HOMA-IR value in



































































































Figure 1: The effect of methyl-GBB administration on plasma EPA (a) and DHA (b) concentrations, cardiac tissue carnitine content (c),
mitochondrial LCAC content (d), and plasma free fatty acid concentration (e) after 12 weeks of treatment. Each value was calculated as
the mean ± S:E:M: of 7 rats for (a) and (b), 6 rats for (c) and (e), and 8(7) rats for (d). ∗Significantly different from the Zucker fa/fa
control group; #significantly different from the Zucker lean rat group (ANOVA followed by Tukey’s test; P < 0:05).
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control group (Figure 3(c)). The lactate plasma concentra-
tion was determined in the fed state and was significantly
higher (2.5-fold) in the Zucker fa/fa rat control group than
in the Zucker lean rats; however, treatment with methyl-
GBB significantly decreased the plasma lactate level by 48%,
indicating more complete glucose metabolism (Figure 3(d)).
Because methyl-GBB treatment was found to improve
insulin sensitivity in Zucker fa/fa rats, the glucose oxidation
rate was measured in isolated perfused normoxic rat hearts.
Glucose utilization was significantly impaired in Zucker fa/fa
control rat hearts, with a 2.7-fold decrease compared to that
in Zucker lean rat hearts. Treatment with methyl-GBB
increased glucose utilization close to the level observed in
the Zucker lean rat group (Figure 3(e)). Mitochondrial fatty
acid and pyruvate metabolism were evaluated in cardiac
fibres from nonischaemic areas of the heart. Methyl-GBB
treatment significantly decreased the CPT I-dependent oxi-
dative phosphorylation- (OXPHOS-) coupled mitochondrial
metabolism of long-chain PCoA by 40% compared to that of
the Zucker fa/fa control group (Figure 3(f)). In addition,
OXPHOS-coupled pyruvate metabolism was significantly
facilitated in methyl-GBB-treated Zucker rats compared to
Zucker lean rats (Figure 3(f)).
Wemeasured the protein phosphorylation levels of phos-
phorylated Akt (P-Akt) and standardized them to the total
Akt level. The P-Akt level was significantly lower in the
Zucker fa/fa control group than in the Zucker lean group.
The P-Akt level in methyl-GBB-treated rat hearts was close
to that in Zucker lean rat hearts (Figure 3(g)). The effects of
methyl-GBB on the expression of PPARα/PGC1α target
genes related to fatty acid and glucose metabolism were
determined in cardiac tissues. Treatment with methyl-GBB
significantly increased the expression of CPT IB, ACOX,
and ACSL up to 1.9-fold when compared to both Zucker lean
and Zucker fa/fa control rats (Figure 3(h)). Moreover, the
expression of the PDK4 gene was significantly upregulated
2.5-fold in methyl-GBB-treated rat hearts, indicating activa-
tion of the PPARα/PGC1α pathway (Figure 3(h)). Together,
treatment with methyl-GBB improves insulin sensing,
decreases fatty acid levels, and, in turn, increases glucose
metabolism.
4. Discussion
The present study shows that the cardioprotective drug
methyl-GBB can decrease I/R damage, diminish energy
metabolism dysfunction in mitochondria, and reduce
glucose-lactate metabolism disturbances in Zucker rats with
metabolic syndrome. The data for the first time show that a
significant decrease in fatty acid oxidation in mitochondria
by methyl-GBB treatment results in increased plasma avail-
ability of PUFAs. Moreover, an increase in PUFA availability
was also observed in normoglycaemic mice treated with
methyl-GBB, indicating that a pharmacological decrease in
fatty acid metabolism is a viable option to further increase
PUFA availability.
Treatment with methyl-GBB increases plasma concen-
trations of PUFAs, particularly that of EPA, and decreases
the levels of acylcarnitines. Previous studies have shown that
long-term treatment with PUFAs provides cardioprotection
in rats in vivo [32]. While CD36-mediated transport is piv-
otal for FA oxidation to support myocardial contractile func-
tion [33], lipotoxicity, in turn, is a well-known paradigm
based on cardiac imbalance between reduced utilization of
FAs and noninterrupted FA delivery [34]. Thus, ongoing
CPT I-dependent metabolism of FAs and subsequent accu-
mulation of saturated LCAC is known to impair mitochon-
drial functionality, which further damages the myocardium
after I/R [35, 36]. In a recent study, we demonstrated that
the accumulation of LCAC in mitochondria during ischae-
mia inhibits ATP synthesis, enhances ROS production, and
induces I/R damage [30]. Here, we show that pharmacologi-
cally limited fatty acid oxidation in methyl-GBB-treated
Zucker fa/fa rats decreases the LCAC content in cardiac
mitochondria and elevates PUFA levels. These changes are
accompanied by the prevention of I/R-induced increases in
ROS production. As a result, a marked 51% decrease in IS
is achieved even in obese Zucker rats with metabolic syn-
drome and severely impaired energy metabolism.
LCAC accumulation induces insulin resistance by inhi-
biting the Akt-mediated signalling pathway [29]. Recently,
we showed that methyl-GBB, by decreasing LCAC tissue
levels, improves insulin sensitivity and glucose tolerance test
Table 1: The effects of methyl-GBB administration on triglyceride, total cholesterol, ASAT and ALAT concentrations in fed rat plasma, and




Triglycerides, mM 0:18 ± 0:02 1:55 ± 0:23# 1:56 ± 0:52#
Total cholesterol, mg/100ml 48 ± 4 108 ± 3# 113 ± 7#
ASAT, U/l 47:6 ± 1:5 48:7 ± 3:5 45:9 ± 1:3
ALAT, U/l 23:5 ± 1:7 39:8 ± 3:0# 38:7 ± 2:1#
Body weight gain, g +241 ± 10 +414 ± 10# +390 ± 14#
Heart to body weight, mg/g 3:70 ± 0:23 2:97 ± 0:09# 2:97 ± 0:10#
Liver to body weight, mg/g 34:4 ± 0:6 36:4 ± 1:1 35:4 ± 0:7
Kidney to body weight, mg/g 5:82 ± 0:07 4:61 ± 0:08 4:47 ± 0:08
Each value was calculated as themean ± S:E:M: of 6 rats for triglyceride and total cholesterol concentrations, 8 rats for ASAT and ALAT levels, and 10 rats for
body weight gain. #Significantly different from the Zucker lean group (ANOVA followed by Tukey’s test; P < 0:05).
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responses [37]. Moreover, the levels of PUFAs have a strong
positive correlation with insulin sensitivity [38], and
improvement in insulin sensitivity after treatment with
EPA was shown to result in functional improvements in glu-
cose and fatty acid uptake and cardiomyocyte shortening
[39]. In the present study, Akt phosphorylation was pre-
served, insulin sensitivity was significantly improved, and
glucose and pyruvate metabolism was facilitated. Akt phos-
phorylation is another parameter that could be increased
not only due to the decrease in LCAC availability but also
due to the increase in PUFA availability [40]. Overall, phar-
macological limitation of fatty acid oxidation improves insu-
lin sensitivity in Zucker rats.
In insulin-resistant tissues, the accumulation of lipids
and their metabolites inhibits the metabolism of pyruvate
[41, 42]; this leads to a situation where glycolysis is not
coupled to oxidative phosphorylation. As a result, the lactate
concentration in plasma is increased to the level typical of the
lactate threshold induced by excessive physical activities. In
this state, pyruvate oxidation in the mitochondria is signifi-
cantly decreased, followed by the formation of lactate and
elevated lactate plasma concentrations [37, 43–45]. In mor-
bidly obese Zucker rats, the lactate plasma concentration is
increased almost 3-fold, while methyl-GBB treatment signif-
icantly improves pyruvate metabolism in mitochondria and
decreases the lactate concentration almost to the control
level. Recently, we confirmed that the effects related to insu-
lin sensitization and the facilitation of pyruvate and lactate
oxidation depend mostly on a decrease in the LCAC content
in muscles [29, 41], while the current study for the first time
confirms that these effects also apply to cardiac tissues from
animals with metabolic syndrome. Overall, facilitation of glu-
cose metabolism by the activation of pyruvate metabolism in
mitochondria could also be partially responsible for the anti-
infarction effect of methyl-GBB.
Current findings further indicate that treatment with
methyl-GBB prevents an I/R-induced increase in mitochon-
drial ROS production under conditions of limited oxidative
phosphorylation. Since it has been shown that the accumula-
tion of LCAC in ischaemic cardiac mitochondria promotes
ROS production due to the inhibition of oxidative phosphor-
ylation [30, 46], the observed prevention of oxidative stress in
ischaemic hearts by methyl-GBB treatment is more likely
associated with the prevention of LCAC accumulation dur-
ing ischaemia. Moreover, activation of mitochondrial respi-
ration and FA oxidation decreases lipotoxicity [47], and it
has been suggested that stimulation of fatty acid oxidation
during reperfusion could be beneficial against I/R-induced
oxidative stress [48]. Treatment with methyl-GBB increases
mitochondrial fatty acid oxidation after ischaemia, thus
ensuring effective utilization of accumulated fatty acid inter-
mediates and subsequent reduction of oxidative stress. Over-
all, these results indicate that a pharmacological decrease in
the LCAC content in cardiac mitochondria attenuates ROS
production under conditions of limited oxidative phosphor-
ylation after I/R and protects against myocardial damage.
Previously, it was shown that methyl-GBB limits I/R
damage in animals with intact glucose metabolism [22, 23],
while the present findings extend the cardioprotective effect
to conditions with markedly impaired cardiac glucose metab-
olism, such as metabolic syndrome. The current results















































Figure 2: The effect of methyl-GBB administration on myocardial infarct size (a, b) and heart functional parameters (c–g) in Langendorff-
perfused isolated hearts and the flux control factor (h) and mitochondrial ROS production (i) in permeabilized cardiac fibres from normoxic
nonrisk (NR) and reperfused area at risk (R) regions of the heart after 12 weeks of treatment. Each value was calculated as themean ± S:E:M:
of 7 hearts in the Zucker lean group, 9 hearts in the methyl-GBB-treated group, and 10 hearts in the Zucker fa/fa control group for (a) and (b)
and 8(7) hearts for (c–g), and 6 hearts for (h) and (i). ∗Significantly different from the Zucker fa/fa control group; #significantly different from
the Zucker lean rat group (Kruskal-Wallis test followed by Dunn’s multiple comparison test; P < 0:05 for (a), ANOVA followed by Tukey’s
test; P < 0:05 for (b), two-way ANOVA followed by Tukey’s test; P < 0:05 for (c–g)). $Significantly different from the respective Zucker fa/fa
control (NR or R) group. &Significantly different from the respective normoxic (NR) group (ANOVA followed by Tukey’s test; P < 0:05).















































































































































































































Figure 3: The effects of methyl-GBB administration on blood glucose (a), insulin (b), HOMA-IR (c), plasma lactate (d) concentrations,
glucose oxidation in isolated Langendorff-perfused rat hearts (e), and pyruvate and CPT I-dependent fatty acid metabolism in cardiac
fibres (f) under normoxic conditions, Akt phosphorylation (g), and the expression of genes related to fatty acid and glucose metabolism
(h) after 12 weeks of treatment. Representative Western blots for Akt phosphorylation are presented in (g). Each value was calculated as
the mean ± S:E:M: of 6 rats for (d) and (f–h) and of 7-8 rats for (a–c) and (e). ∗Significantly different from the Zucker fa/fa control group
(ANOVA followed by Tukey’s test/Kruskal-Wallis followed by Dunn’s test; P < 0:05). #Significantly different from the Zucker lean group
(ANOVA followed by Tukey’s test/Kruskal-Wallis followed by Dunn’s test; P < 0:05).
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methyl-GBB is related to changes in fatty acid handling.
Thus, EPA and DHA each can protect the heart against myo-
cardial infarction damage [40], and treatment with methyl-
GBB increases the availability of the aforementioned PUFAs.
In addition, earlier observations by Harmancey and col-
leagues [49] indicate that the improved utilization of long-
chain fatty acids during reperfusion leads to better recovery
in insulin-resistant hearts. While treatment with methyl-
GBB decreases CPT I-dependent long-chain fatty acid
conversion to LCAC and overall fatty acid metabolism, a sig-
nificant increase in fatty acid mitochondrial utilization in
areas at risk compared to that in normoxic areas from the
same heart was observed in methyl-GBB-treated hearts after
reperfusion but not in control Zucker fa/fa rat hearts.
Changes in the fatty acid metabolism pattern are accompa-
nied by improved cardiac functionality in methyl-GBB-
treated Langendorff-perfused isolated Zucker fa/fa rat hearts
during reperfusion. This effect was not observed before in
normoglycaemic animals [22, 23]. Significant increases in
the expression of several PPARα/PGC1α target genes
involved in fatty acid oxidation might at least partially be
the result of increased PUFA levels [50, 51] and could be
responsible for increased fatty acid oxidation recovery in
reperfused tissues.
5. Conclusions
The current study highlights the potential benefits of phar-
macologically increasing PUFAs and decreasing LCAC levels
by methyl-GBB to improve insulin sensitivity and mitochon-
drial functionality as well as the cardioprotective effect of
methyl-GBB in treating metabolic syndrome. Presented here
is a strategy to accumulate PUFAs and to facilitate overall
fatty acid metabolism during reperfusion to decrease LCAC
availability. This leads to the protection of the myocardium
against damage induced by ischaemia under complex meta-
bolic conditions and raises expectations for the successful
translation of such a strategy to clinical settings.
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